MD Anderson in Sugar Land
Welcome,         Profile    Billing    Logout  
 1076 Trials 
434 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Benson, Al B
BTCRC-GI15-015, NCT03283761: FOLFOX-A in the Treatment of Metastatic or Advanced Unresectable Gastric, Gastro-Esophageal Junction Adenocarcinoma

Completed
2
39
US
Nab-paclitaxel 150 mg/m^2, Abraxane®, Oxaliplatin 85 mg/m^2, Eloxatin, 5-FU 1200 mg/m^2 x 2 D, Adrucil, Fluorouracil, Leucovorin 400 mg/m^2
Al B. Benson, III, MD, Celgene Corporation, Big Ten Cancer Research Consortium
Gastro-Esophageal Junction Adenocarcinoma, Gastric Cancer
12/22
01/23
NCT03861702: Liposomal Irinotecan in Combination With Oxaliplatin, Leucovorin, and 5-fluorouracil for Patients With Locally Advanced Pancreatic Carcinoma:

Active, not recruiting
2
28
US
FOLFOX regimen, Liposomal Irinotecan, nal-Irinotecan
Nelson Yee, Ipsen
Locally Advanced Pancreatic Carcinoma(LAPC)
08/23
08/24
NCT04505839: First-In-Human Dose-Escalation Study of STP1002 in Patients With Advanced-Stage Solid Tumors

Completed
1
32
US
STP1002, Basroparib
ST Pharm Co., Ltd., KCRN Research, LLC
Advanced Solid Tumor
03/23
03/23
Carey, Lisa A
EMBER-3, NCT04975308 / 2021-000079-35: A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer

Recruiting
3
860
Europe, Japan, US, RoW
Imlunestrant, LY3484356, Exemestane, Fulvestrant, Abemaciclib, LY2835219
Eli Lilly and Company, Eli Lilly and Company
Breast Neoplasms, Neoplasm Metastasis
04/24
08/27
NCT05415137 / 2022-001012-26: Efficacy and Safety of Intravenous Efzofitimod in Patients With Pulmonary Sarcoidosis

Recruiting
3
264
Europe, Japan, US, RoW
Efzofitimod 3 mg/kg, ATYR1923, KRP-R120, Efzofitimod 5 mg/kg, Placebo
aTyr Pharma, Inc., Kyorin Pharmaceutical Co.,Ltd
Pulmonary Sarcoidosis
12/24
01/25
HARMONIA, NCT05207709: Ribociclib vs. Palbociclib in Patients With Advanced Breast Cancer Within the HER2-Enriched Intrinsic Subtype

Recruiting
3
456
Europe, US
Ribociclib + Letrozole OR Fulvestrant, Palbociclib + Letrozole OR Fulvestrant, Paclitaxel +/- Tislelizumab
SOLTI Breast Cancer Research Group, Novartis, Alliance Foundation Trials, LLC.
Metastatic Breast Cancer
03/26
03/27
A011801, NCT04457596: T-DM1 and Tucatinib Compared With T-DM1 Alone in Preventing Relapses in People With High Risk HER2-Positive Breast Cancer, the CompassHER2 RD Trial

Calendar Jan 2028 - Dec 2028: From CompassHER2 RD trial in combination with Kadcyla for HER2+ breast cancer
Recruiting
3
1031
Canada, US
Trastuzumab Emtansine, Placebo Administration, Tucatinib, Questionnaire Administration, Quality-of-Life Assessment
Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI), Seagen Inc.
Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, HER2 Positive Breast Carcinoma, Invasive Breast Carcinoma, Multifocal Breast Carcinoma, Prognostic Stage I Breast Cancer AJCC v8, Prognostic Stage IA Breast Cancer AJCC v8, Prognostic Stage IB Breast Cancer AJCC v8, Prognostic Stage II Breast Cancer AJCC v8, Prognostic Stage IIA Breast Cancer AJCC v8, Prognostic Stage IIB Breast Cancer AJCC v8, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8, Synchronous Bilateral Breast Carcinoma
01/28
05/35
HER2CLIMB-04, NCT04539938: A Study of Tucatinib Plus Trastuzumab Deruxtecan in HER2+ Breast Cancer

Active, not recruiting
2
70
US
tucatinib, TUKYSA, ARRY-380, ONT-380, trastuzumab deruxtecan, T-DXd, Enhertu, DS-8201
Seagen Inc.
HER2 Positive Breast Cancer
07/24
10/25
MARGOT, NCT04425018: MARGetuximab Or Trastuzumab

Active, not recruiting
2
174
US
Paclitaxel, Taxol, Onxal, Pertuzumab, Perjeta, Margetuximab, Margenza, Trastuzumab, Herceptin, Kanjinti, Ogivri, Herzuma
Dana-Farber Cancer Institute, MacroGenics, Translational Breast Cancer Research Consortium
Breast Cancer, Stage II Breast Cancer, Stage III Breast Cancer, HER2-positive Breast Cancer
10/24
07/27
NCT05892614: Study to Evaluate the Efficacy, Safety, and Tolerability of Efzofitimod in Patients With Systemic Sclerosis (SSc)-Related Interstitial Lung Disease (ILD) (SSc-ILD)

Recruiting
2
25
US
efzofitimod 450 mg, efzofitimod 270 mg, Placebo
aTyr Pharma, Inc.
Interstitial Lung Disease
12/24
12/24
Saci-IO HR+, NCT04448886: Sacituzumab Govitecan +/- Pembrolizumab In HR+ / HER2 - MBC

Hourglass Jan 2021 - Jan 2021 : Data from trial for HR+ / HER2 – metastatic breast cancer
Active, not recruiting
2
110
US
Pembrolizumab, Keytruda, Sacituzumab Govitecan, TRODELVY
Ana C Garrido-Castro, MD, Merck Sharp & Dohme LLC, Gilead Sciences
Invasive Breast Cancer, Metastatic Breast Cancer, HR-Positive Breast Cancer, HER2-negative Breast Cancer
03/24
06/27
ADEPT, NCT04569747: A Single Arm Phase II Study of ADjuvant Endocrine Therapy, Pertuzumab, and Trastuzumab for Patients With Anatomic Stage I Hormone Receptor-positive, HER2-positive Breast Cancer

Recruiting
2
375
US
Pertuzumab+TRASTUZUMAB, PHESGO, ADJUVANT ENDOCRINE THERAPY, Letrozole, Anastrozole, Exemestane, Tamoxifen, Leuprolide, or other LHRH agonist (per investigator discretion)
Dana-Farber Cancer Institute, Genentech, Inc.
HER2-positive Breast Cancer, Invasive Carcinoma of the Breast, Breast Cancer, Node Negative Breast Cancer, Micrometastasis Breast Cancer, Hormone Receptor Positive Breast Cancer
09/26
09/30
TBCRC 058, NCT06099769: A Study of Enzalutamide, Enzalutamide in Combination With Mifepristone, or Chemotherapy in People With Metastatic Breast Cancer

Recruiting
2
201
US
Enzalutamide, Mifepristone, TPC
Memorial Sloan Kettering Cancer Center, Astellas Pharma US, Inc., Breast Cancer Research Foundation, Corcept Therapeutics
Metastatic Breast Cancer
10/27
10/27
EMBER, NCT04188548 / 2019-003581-41: A Study of LY3484356 in Participants With Advanced or Metastatic Breast Cancer or Endometrial Cancer

Active, not recruiting
1
500
Europe, Japan, US, RoW
LY3484356, Imlunestrant, Abemaciclib, LY2835219, Everolimus, Alpelisib, Trastuzumab, Aromatase Inhibitor (AI), Pertuzumab
Eli Lilly and Company
Breast Cancer, Advanced Breast Cancer, Metastatic Breast Cancer, Endometrial Cancer
06/20
12/27
HARMONY, NCT03769415: Harnessing Analysis RNA Expression and Molecular Subtype to Optimize Novel TherapY MBCA

Recruiting
N/A
500
US
Intrinsic Subtyping of Primary Breast Cancer
UNC Lineberger Comprehensive Cancer Center, Veracyte, Inc.
Breast Cancer
12/30
12/30
Dragnev, Konstantin H
ASTRIDE, NCT05468489: To Evaluate Efficacy and Safety of Serplulimab + Chemotherapy (Carboplatin- Etoposide) in US Patients With ES-SCLC

Recruiting
3
200
US
Serplulimab + chemotherapy (carboplatin-etoposide), Atezolizumab + chemotherapy (carboplatin-etoposide)
Shanghai Henlius Biotech
Extensive Stage Small Cell Lung Cancer
10/24
12/25
SUNRAY-01, NCT06119581: A Study of LY3537982 Plus Immunotherapy With or Without Chemotherapy in Participants With Non-Small Cell Lung Cancer (NSCLC) With a Change in a Gene Called KRAS G12C

Recruiting
3
1016
Europe, Canada, Japan, US, RoW
LY3537982, Pembrolizumab, Placebo, Cisplatin, Carboplatin, Pemetrexed
Eli Lilly and Company, Loxo Oncology, Inc.
Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis
10/26
10/29
NCT05578326: Study of Trilaciclib and Lurbinectidin

Recruiting
2
30
US
Trilaciclib, Lurbinectedin
UNC Lineberger Comprehensive Cancer Center, G1 Therapeutics, Inc.
Lung Cancer, Small-cell Lung Cancer
07/24
07/26
A071401, NCT02523014: Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas

Recruiting
2
124
US
Vismodegib, GDC-0449, FAK Inhibitor GSK2256098, Capivasertib, AZD5363, Abemaciclib
Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI), GlaxoSmithKline, Genentech, Inc., Brain Science Foundation
Intracranial Meningioma, Recurrent Meningioma, NF2 Gene Mutation
10/24
10/24
NCT06362369: A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy

Recruiting
1/2
126
US
Alintegimod, 7HP349, Ipilimumab, Yervoy, Nivolumab, Opdivo
7 Hills Pharma, LLC
Advanced Cancer, Advanced Solid Tumor, Melanoma, Metastasis, Pleural Mesothelioma, Renal Cell Carcinoma, MSI-High, Mismatch Repair Deficiency, Colorectal Cancer, Hepatocellular Carcinoma, Hepatocellular Cancer, Renal Cell Cancer, Kidney Cancer, Skin Cancer, Non Small Cell Lung Cancer, NSCLC, Anaplastic Lymphoma Kinase Genomic Tumor Aberrations, ALK Genomic Tumor Aberrations
12/27
12/28
NCT04795713: Study of MT-6402 in Subjects With Advanced Solid Cancer That Expresses PD-L1

Recruiting
1
138
US
MT-6402
Molecular Templates, Inc.
Advanced Solid Tumor, Non-small Cell Lung Cancer, Squamous Cell Carcinoma of Head and Neck
04/25
05/26
Carlson, Jay W
SWOG S2302, NCT05633602: Ramucirumab Plus Pembrolizumab vs Usual Care for Treatment of Stage IV or Recurrent Non-Small Cell Lung Cancer Following Immunotherapy, Pragmatica-Lung Study

Recruiting
3
700
US
Chemotherapy, Chemo, Chemotherapy (NOS), Chemotherapy, Cancer, General, Pembrolizumab, Keytruda, Lambrolizumab, MK-3475, SCH 900475, Ramucirumab, Anti-VEGFR-2 Fully Human Monoclonal Antibody IMC-1121B, Cyramza, IMC-1121B, LY3009806
SWOG Cancer Research Network, National Cancer Institute (NCI), Eli Lilly and Company, Merck Sharp & Dohme LLC
Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
03/25
03/28
PACES, NCT01349881: S0820, Adenoma and Second Primary Prevention Trial

Active, not recruiting
3
354
US
Eflornithine placebo & sulindac placebo, eflornithine & sulindac placebo, Eflornithine placebo & sulindac, Eflornithine plus sulindac
SWOG Cancer Research Network, National Cancer Institute (NCI), Cancer Prevention Pharmaceuticals, Inc.
Colorectal Neoplasms
02/27
02/32
A011801, NCT04457596: T-DM1 and Tucatinib Compared With T-DM1 Alone in Preventing Relapses in People With High Risk HER2-Positive Breast Cancer, the CompassHER2 RD Trial

Calendar Jan 2028 - Dec 2028: From CompassHER2 RD trial in combination with Kadcyla for HER2+ breast cancer
Recruiting
3
1031
Canada, US
Trastuzumab Emtansine, Placebo Administration, Tucatinib, Questionnaire Administration, Quality-of-Life Assessment
Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI), Seagen Inc.
Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, HER2 Positive Breast Carcinoma, Invasive Breast Carcinoma, Multifocal Breast Carcinoma, Prognostic Stage I Breast Cancer AJCC v8, Prognostic Stage IA Breast Cancer AJCC v8, Prognostic Stage IB Breast Cancer AJCC v8, Prognostic Stage II Breast Cancer AJCC v8, Prognostic Stage IIA Breast Cancer AJCC v8, Prognostic Stage IIB Breast Cancer AJCC v8, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8, Synchronous Bilateral Breast Carcinoma
01/28
05/35
DRAMMATIC, NCT04071457: S1803, Lenalidomide +/- Daratumumab/rHuPh20 as Post-ASCT Maintenance for MM w/MRD to Direct Therapy Duration

Hourglass Jan 2023 - Jun 2023 : From trial for patients with r/r multiple myeloma treated with an IMiD and PI
Recruiting
3
1100
Canada, US
Lenalidomide, CC-5013, Revlimid, Daratumumab/rHuPH20
SWOG Cancer Research Network, National Cancer Institute (NCI), Janssen, LP
Multiple Myeloma
07/29
07/40
CIRCULATE-US, NCT05174169: Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease

Recruiting
2/3
1912
Canada, US
Signatera test, mFOLFOX6 3-6 month, CAPOX 3 month, mFOLFIRINOX, mFOLFOX6 6 month, CAPOX 6 month
NRG Oncology, Natera, Inc., National Cancer Institute (NCI)
Stage III Colon Cancer
03/29
03/30
A071401, NCT02523014: Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas

Recruiting
2
124
US
Vismodegib, GDC-0449, FAK Inhibitor GSK2256098, Capivasertib, AZD5363, Abemaciclib
Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI), GlaxoSmithKline, Genentech, Inc., Brain Science Foundation
Intracranial Meningioma, Recurrent Meningioma, NF2 Gene Mutation
10/24
10/24
PRECISION 1, NCT05103358: Phase 2 Basket Trial of Nab-sirolimus in Patients With Malignant Solid Tumors With Pathogenic Alterations in TSC1/TSC2 Genes

Active, not recruiting
2
120
US, RoW
nab-sirolimus, ABI-009
Aadi Bioscience, Inc.
Tumor, Tumor, Solid, Metastasis, Metastatic Cancer, Cancer, Cancer Metastatic, Tumors, Neoplasms, Neoplasm Metastasis, Solid Tumor, Advanced Solid Tumor, Advanced Cancer, Malignant Solid Tumor, Malignant Solid Neoplasm, Malignant Neoplasm, Malignant Tumor, TSC, TSC1, TSC2, Metastatic Solid Tumor, Metastatic Neoplasm
12/24
12/25
NCT04647916: Testing Sacituzumab Govitecan Therapy in Patients With HER2-Negative Breast Cancer and Brain Metastases

Recruiting
2
44
US
Sacituzumab Govitecan, hRS7-SN38 Antibody Drug Conjugate, IMMU-132, RS7-SN38, Sacituzumab Govitecan-hziy, Trodelvy
SWOG Cancer Research Network, National Cancer Institute (NCI), Gilead Sciences
Anatomic Stage IV Breast Cancer AJCC v8, Invasive Breast Carcinoma, Metastatic HER2 Negative Breast Carcinoma, Metastatic Malignant Neoplasm in the Brain, Prognostic Stage IV Breast Cancer AJCC v8
02/25
12/26
Deming, Richard L
SWOG S2302, NCT05633602: Ramucirumab Plus Pembrolizumab vs Usual Care for Treatment of Stage IV or Recurrent Non-Small Cell Lung Cancer Following Immunotherapy, Pragmatica-Lung Study

Recruiting
3
700
US
Chemotherapy, Chemo, Chemotherapy (NOS), Chemotherapy, Cancer, General, Pembrolizumab, Keytruda, Lambrolizumab, MK-3475, SCH 900475, Ramucirumab, Anti-VEGFR-2 Fully Human Monoclonal Antibody IMC-1121B, Cyramza, IMC-1121B, LY3009806
SWOG Cancer Research Network, National Cancer Institute (NCI), Eli Lilly and Company, Merck Sharp & Dohme LLC
Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
03/25
03/28
PACES, NCT01349881: S0820, Adenoma and Second Primary Prevention Trial

Active, not recruiting
3
354
US
Eflornithine placebo & sulindac placebo, eflornithine & sulindac placebo, Eflornithine placebo & sulindac, Eflornithine plus sulindac
SWOG Cancer Research Network, National Cancer Institute (NCI), Cancer Prevention Pharmaceuticals, Inc.
Colorectal Neoplasms
02/27
02/32
A011801, NCT04457596: T-DM1 and Tucatinib Compared With T-DM1 Alone in Preventing Relapses in People With High Risk HER2-Positive Breast Cancer, the CompassHER2 RD Trial

Calendar Jan 2028 - Dec 2028: From CompassHER2 RD trial in combination with Kadcyla for HER2+ breast cancer
Recruiting
3
1031
Canada, US
Trastuzumab Emtansine, Placebo Administration, Tucatinib, Questionnaire Administration, Quality-of-Life Assessment
Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI), Seagen Inc.
Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, HER2 Positive Breast Carcinoma, Invasive Breast Carcinoma, Multifocal Breast Carcinoma, Prognostic Stage I Breast Cancer AJCC v8, Prognostic Stage IA Breast Cancer AJCC v8, Prognostic Stage IB Breast Cancer AJCC v8, Prognostic Stage II Breast Cancer AJCC v8, Prognostic Stage IIA Breast Cancer AJCC v8, Prognostic Stage IIB Breast Cancer AJCC v8, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8, Synchronous Bilateral Breast Carcinoma
01/28
05/35
DRAMMATIC, NCT04071457: S1803, Lenalidomide +/- Daratumumab/rHuPh20 as Post-ASCT Maintenance for MM w/MRD to Direct Therapy Duration

Hourglass Jan 2023 - Jun 2023 : From trial for patients with r/r multiple myeloma treated with an IMiD and PI
Recruiting
3
1100
Canada, US
Lenalidomide, CC-5013, Revlimid, Daratumumab/rHuPH20
SWOG Cancer Research Network, National Cancer Institute (NCI), Janssen, LP
Multiple Myeloma
07/29
07/40
CIRCULATE-US, NCT05174169: Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease

Recruiting
2/3
1912
Canada, US
Signatera test, mFOLFOX6 3-6 month, CAPOX 3 month, mFOLFIRINOX, mFOLFOX6 6 month, CAPOX 6 month
NRG Oncology, Natera, Inc., National Cancer Institute (NCI)
Stage III Colon Cancer
03/29
03/30
A071401, NCT02523014: Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas

Recruiting
2
124
US
Vismodegib, GDC-0449, FAK Inhibitor GSK2256098, Capivasertib, AZD5363, Abemaciclib
Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI), GlaxoSmithKline, Genentech, Inc., Brain Science Foundation
Intracranial Meningioma, Recurrent Meningioma, NF2 Gene Mutation
10/24
10/24
NCT03994796: Genetic Testing in Guiding Treatment for Patients With Brain Metastases

Recruiting
2
186
US
Abemaciclib, PI3K Inhibitor paxalisib, Entrectinib, Adagrasib, MRTX849
Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI), Mirati Therapeutics Inc., Genentech, Inc., Eli Lilly and Company, Kazia Therapeutics Limited
CDK Gene Mutation, Metastatic Malignant Neoplasm in the Brain, Metastatic Malignant Solid Neoplasm, NTRK Family Gene Mutation, PI3K Gene Mutation, ROS1 Gene Mutation, KRAS G12C Mutation
10/24
06/25
NCT04647916: Testing Sacituzumab Govitecan Therapy in Patients With HER2-Negative Breast Cancer and Brain Metastases

Recruiting
2
44
US
Sacituzumab Govitecan, hRS7-SN38 Antibody Drug Conjugate, IMMU-132, RS7-SN38, Sacituzumab Govitecan-hziy, Trodelvy
SWOG Cancer Research Network, National Cancer Institute (NCI), Gilead Sciences
Anatomic Stage IV Breast Cancer AJCC v8, Invasive Breast Carcinoma, Metastatic HER2 Negative Breast Carcinoma, Metastatic Malignant Neoplasm in the Brain, Prognostic Stage IV Breast Cancer AJCC v8
02/25
12/26
Ueno, Naoto
NCT05438329: First-in-human Study of DB-1305/BNT325 for Advanced/Metastatic Solid Tumors

Recruiting
1/2
842
US, RoW
DB-1305/BNT325, DB-1305/BNT325 for Injection, Pembrolizumab, BNT327
DualityBio Inc., BioNTech SE
Advanced Solid Tumor
06/25
06/25
DROPLET-BC, NCT04671498: Droplet-BC Screening Test for the Detection of Breast Cancer, the Study

Recruiting
N/A
1200
US
Biospecimen Collection, Droplet-BC Test, Electronic Health Record Review
Preferred Medicine, Inc, M.D. Anderson Cancer Center
Breast Carcinoma
12/22
12/22
Jones, David R
NCT04950127 / 2021-000007-21: Global Linerixibat Itch Study of Efficacy and Safety in Primary Biliary Cholangitis (PBC) (GLISTEN)

Active, not recruiting
3
241
Europe, Canada, Japan, US, RoW
Linerixibat, Placebo
GlaxoSmithKline
Pruritus
10/24
01/25
LLSAT, NCT04167358 / 2019-003158-10: Linerixibat Long-term Safety, and Tolerability Study

Recruiting
3
305
Europe, Canada, Japan, US, RoW
Linerixibat
GlaxoSmithKline, GlaxoSmithKline LLC, GlaxoSmithKline Research & Development Limited
Cholestasis
02/27
02/27
J1414, NCT02259621: Neoadjuvant Nivolumab, or Nivolumab in Combination With Ipilimumab, in Resectable NSCLC

Checkmark In adults with untreated, surgically resectable early (stage I, II, or IIIA) NSCLC
May 2018 - May 2018: In adults with untreated, surgically resectable early (stage I, II, or IIIA) NSCLC
Checkmark ASCO 2016
May 2016 - May 2016: ASCO 2016
Active, not recruiting
2
39
Canada, US
Nivolumab, BMS-936558 or MDX1106, Carboplatin, Paraplatin, Paclitaxel, Taxol, Onxal, Ipilimumab
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Bristol-Myers Squibb
Non-Small Cell Lung Cancer
10/22
10/27
PACIFIC, NCT05525520: Study to Evaluate EP547 in Subjects With Cholestatic Pruritus Due to Primary Biliary Cholangitis or Primary Sclerosing Cholangitis

Active, not recruiting
2
58
Europe, Canada, US, RoW
EP547, Placebo
Escient Pharmaceuticals, Inc
Pruritus
07/24
09/24
NCT04594694 / 2018-002575-17: Study of OCA in Combination With BZF Evaluating Efficacy, Safety, and Tolerability in Participants With PBC

Active, not recruiting
2
72
Europe, RoW
Obeticholic acid, Bezafibrate 200 MG, OCA Placebo, Bezafibrate 200 mg Placebo, Bezafibrate 400 MG, Bezafibrate 400 mg Placebo, OCA, Bezafibrate
Intercept Pharmaceuticals
Primary Biliary Cholangitis
10/25
12/25
Reynolds, Christopher
SYMPHONY-1, NCT04224493 / 2019-003333-42: Study of Tazemetostat Versus Placebo When Given in Combination With Lenalidomide and Rituximab in Participants With Relapsed/Refractory Follicular Lymphoma

Hourglass Jan 2023 - Dec 2023 : First interim futility data from P3 portion of P1b/3 SYMPHONY-1 trial in combination with Rituxan for relapsed/refractory follicular lymphoma
Jan 2023 - Dec 2023: DOR/PFS data from P1b portion of P1b/3 SYMPHONY-1 trial in combination with Revlimid and Rituxan for relapsed/refractory follicular lymphoma
Hourglass Jan 2022 - Dec 2022 : Completion of enrollment of P3 portion of P1b/3 trial for r/r follicular lymphoma
Checkmark Data from SYMPHONY-1 trial in combination with Rituxan and Revlimid for follicular lymphoma
Jun 2022 - Jun 2022: Data from SYMPHONY-1 trial in combination with Rituxan and Revlimid for follicular lymphoma
More
Recruiting
3
612
Europe, Canada, US, RoW
Tazemetostat, EPZ-6438, IPN60200, Placebo oral tablet, Lenalidomide, Rituximab
Epizyme, Inc.
Relapsed/Refractory Follicular Lymphoma, Follicular Lymphoma, Refractory Follicular Lymphoma
03/26
03/29
A011801, NCT04457596: T-DM1 and Tucatinib Compared With T-DM1 Alone in Preventing Relapses in People With High Risk HER2-Positive Breast Cancer, the CompassHER2 RD Trial

Calendar Jan 2028 - Dec 2028: From CompassHER2 RD trial in combination with Kadcyla for HER2+ breast cancer
Recruiting
3
1031
Canada, US
Trastuzumab Emtansine, Placebo Administration, Tucatinib, Questionnaire Administration, Quality-of-Life Assessment
Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI), Seagen Inc.
Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, HER2 Positive Breast Carcinoma, Invasive Breast Carcinoma, Multifocal Breast Carcinoma, Prognostic Stage I Breast Cancer AJCC v8, Prognostic Stage IA Breast Cancer AJCC v8, Prognostic Stage IB Breast Cancer AJCC v8, Prognostic Stage II Breast Cancer AJCC v8, Prognostic Stage IIA Breast Cancer AJCC v8, Prognostic Stage IIB Breast Cancer AJCC v8, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8, Synchronous Bilateral Breast Carcinoma
01/28
05/35
Gillenwater, Ann M
NCT03769506 / 2018-002513-36: ASP-1929 Photoimmunotherapy (PIT) Study in Recurrent Head/Neck Cancer for Patients Who Have Failed at Least Two Lines of Therapy

Recruiting
3
275
Japan, US, RoW
ASP-1929 Photoimmunotherapy, Physician's Choice SOC
Rakuten Medical, Inc.
Head and Neck Cancer
09/24
12/24
NCT05220748: RM-1995 Photoimmunotherapy, as Monotherapy or Combined With Pembrolizumab, in Patients With Advanced CuSCC and HNSCC

Withdrawn
1
36
NA
RM-1995, Pembrolizumab
Rakuten Medical, Inc.
Cutaneous Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma
01/23
01/23
Valero, Vicente
NCT05035836: A Phase 2 Single-Arm Open-Label Pilot Trial Evaluating Zanidatamab (ZW25) in Patients With Early Stage HER2/Neu Positive (HER2+) Breast Cancer (BC)

Active, not recruiting
2
20
US
Zanidatamab, ZW25, Letrozole, Tamoxifen
M.D. Anderson Cancer Center, Zymeworks BC Inc.
Breast Cancer, HER2-positive
12/24
12/24
ATEMPT 2.0, NCT04893109: Adjuvant T-DM1 vs TH

Recruiting
2
500
US
trastuzumab-emtansine, T-DM1, Kadcyla, Trastuzumab SC, Herceptin Hylecta, Paclitaxel, Taxol, Onxal
Dana-Farber Cancer Institute, Genentech, Inc.
Breast Cancer, HER2-positive Breast Cancer
05/25
05/28
ADEPT, NCT04569747: A Single Arm Phase II Study of ADjuvant Endocrine Therapy, Pertuzumab, and Trastuzumab for Patients With Anatomic Stage I Hormone Receptor-positive, HER2-positive Breast Cancer

Recruiting
2
375
US
Pertuzumab+TRASTUZUMAB, PHESGO, ADJUVANT ENDOCRINE THERAPY, Letrozole, Anastrozole, Exemestane, Tamoxifen, Leuprolide, or other LHRH agonist (per investigator discretion)
Dana-Farber Cancer Institute, Genentech, Inc.
HER2-positive Breast Cancer, Invasive Carcinoma of the Breast, Breast Cancer, Node Negative Breast Cancer, Micrometastasis Breast Cancer, Hormone Receptor Positive Breast Cancer
09/26
09/30
Naing, Aung
NCT05672459: A Safety And Efficacy Study Of HLA-G- Targeted CAR-T Cells IVS-3001 In Subjects With Previously Treated Advanced HLA-G-Positive Solid Tumors

Recruiting
1/2
117
US
Single Injection of IVS-3001- Anti - HLA-G CAR-T cells, Fludarabine phosphate, Cyclophosphamide, leukapheresis
M.D. Anderson Cancer Center, Invectys
Solid Tumor
06/26
12/29
NCT05584670: A First-in-human, Dose Escalation and Dose Expansion Study of SAR445877 in Adult Participants With Advanced Solid Tumors

Recruiting
1/2
285
Europe, US, RoW
SAR445877, Cetuximab, Erbitux
Sanofi
Solid Tumor
01/27
09/28
FORTIFY, NCT05165433: Study of NG-350A Plus Pembrolizumab in Metastatic or Advanced Epithelial Tumours

Recruiting
1a/1b
198
Europe, US
NG-350A plus Pembrolizumab
Akamis Bio, Merck Sharp & Dohme LLC
Epithelial Tumor, Metastatic Cancer
03/25
05/25
NCT04306224: A Study of IMC-002 in Subjects With Metastatic or Locally Advanced Solid Tumors and Relapsed or Refractory Lymphomas

Completed
1
12
US, RoW
IMC-002
ImmuneOncia Therapeutics Inc.
Solid Tumor, Lymphoma
10/22
10/22
NCT04859777: A Study of MPT-0118 in Subjects With Advanced or Metastatic Refractory Solid Tumors

Recruiting
1
70
US
MPT-0118, MPT-0118 + pembrolizumab
Monopteros Therapeutics Inc.
Solid Tumor, Adult, Advanced Solid Tumor, Advanced Cancer, Metastatic Cancer, Refractory Cancer
03/23
03/23
AURELIO-03, NCT04234113: Study of SO-C101 and SO-C101 in Combination With Pembro in Adult Patients With Advanced/Metastatic Solid Tumors

Active, not recruiting
1
200
Europe, US, RoW
SO-C101, SOT101, pembrolizumab
SOTIO Biotech AG, SOTIO Biotech a.s.
Thyroid, Renal Cell Carcinoma, Non Small Cell Lung Cancer, Small-cell Lung Cancer, Bladder Cancer, Melanoma, Merkel Cell Carcinoma, Skin Squamous Cell Carcinoma, Microsatellite Instability High, Triple Negative Breast Cancer, Mesothelioma, Thymic Cancer, Cervical Cancer, Biliary Tract Cancer, Hepatocellular Carcinoma, Ovarian Cancer, Gastric Cancer, Head and Neck Squamous Cell Carcinoma, Anal Cancer
08/24
11/24
NCT05054348: First-in-human Study of IO-108 as Single Agent and in Combination With a PD-1 Immune Check Point Inhibitor in Patients With Advanced Solid Tumors

Completed
1
91
US
IO-108, IO-108 + pembrolizumab combination therapy, IO-108 + Keytruda combination therapy, IO-108 + cemiplimab combination therapy, IO-108 + Libtayo combination therapy
Immune-Onc Therapeutics, Regeneron Pharmaceuticals
Solid Tumor, Adult
04/24
05/24
NPX887-001, NCT06240728: A Study of NPX887 for Participants With Solid Tumors Known to Express HHLA2/B7-H7

Recruiting
1
144
US
NPX887
NextPoint Therapeutics, Inc.
Metastatic Malignant Neoplasm
08/27
08/27
NCT05309187: Dose-Escalation and Dose-Expansion Study of IO-202 and IO-202+Pembrolizumab in Solid Tumors

Completed
1
22
US
IO-202, IO-202 + pembrolizumab combination therapy, IO-202 + Keytruda combination therapy, RP2D of IO-202 + pembrolizumab combination therapy in multiple solid tumor types, RP2D of IO-202 + Keytruda combination therapy
Immune-Onc Therapeutics
Solid Tumor, Adult
03/24
05/24
KEYNOTE-C16, NCT04374877: Study of CHS-388 (Formerly Known as SRF388) in Patients With Advanced Solid Tumors

Recruiting
1
260
US, RoW
CHS-388, Casdozokitug, Pembrolizumab, Keytruda®, Toripalimab, Loqtorzi®
Coherus Biosciences, Inc., Merck Sharp & Dohme LLC
Advanced Solid Tumor, Clear Cell Renal Cell Carcinoma, Hepatocellular Carcinoma, Non-small Cell Lung Cancer
12/25
08/26
NCT06163391: A Study to Assess Safety and Efficacy of SOT201 in Patients With Advanced/Metastatic Cancer

Recruiting
1
40
Europe, US, RoW
SOT201
SOTIO Biotech AG
Advanced Solid Tumor, Metastatic Solid Tumor
10/26
10/26
NCT05669430: A Study of GV20-0251 in Patients With Solid Tumor Malignancies

Recruiting
1
268
US
GV20-0251
GV20 Therapeutics
Solid Tumor, Adult, Refractory Cancer, Bladder Urothelial Carcinoma, Cholangiocarcinoma, Adenocarcinoma of the Colon, Endometrial Carcinoma, Head and Neck Carcinoma, Cutaneous Melanoma, Non-small Cell Lung Cancer, Adenocarcinoma of the Rectum
12/25
06/26
NCT05958199: A Study of NPX267 for Subjects With Solid Tumors Known to Express HHLA2/B7-H7

Recruiting
1
131
US
NPX267
NextPoint Therapeutics, Inc.
Metastatic Malignant Neoplasm
01/26
01/26
NCT06046066: A Phase 1 Study of NM6603 in Advanced Solid Tumors

Recruiting
1
36
US
NM6603
NucMito Pharmaceuticals Co. Ltd.
Cancers
02/26
07/26
Sharma, Priyanka
NeoPACT, NCT03639948: Neoadjuvant Phase II Study of Pembrolizumab And Carboplatin Plus Docetaxel in Triple Negative Breast Cancer

Active, not recruiting
2
120
US
Carboplatin, Docetaxel, Pembrolizumab, Pegfilgrastim
University of Kansas Medical Center, Merck Sharp & Dohme LLC
Triple-negative Breast Cancer
01/22
11/24
NCT04647916: Testing Sacituzumab Govitecan Therapy in Patients With HER2-Negative Breast Cancer and Brain Metastases

Recruiting
2
44
US
Sacituzumab Govitecan, hRS7-SN38 Antibody Drug Conjugate, IMMU-132, RS7-SN38, Sacituzumab Govitecan-hziy, Trodelvy
SWOG Cancer Research Network, National Cancer Institute (NCI), Gilead Sciences
Anatomic Stage IV Breast Cancer AJCC v8, Invasive Breast Carcinoma, Metastatic HER2 Negative Breast Carcinoma, Metastatic Malignant Neoplasm in the Brain, Prognostic Stage IV Breast Cancer AJCC v8
02/25
12/26
NCT02393794: Cisplatin Plus Romidepsin & Nivolumab in Locally Recurrent or Metastatic Triple Negative Breast Cancer (TNBC)

Active, not recruiting
1/2
51
US
Romidepsin, Histone deacetylase inhibitor, Cisplatin, Platinol, Nivolumab, Opdivo
Priyanka Sharma, Celgene Corporation, Bristol-Myers Squibb
Triple-Negative Breast Cancer, Breast Cancer
12/24
07/25
ASSET, NCT05143229: Alpelisib And Sacituzumab Govitecan For Treatment Of Breast Cancer

Recruiting
1
18
US
Alpelisib, Piqray, Sacituzumab govitecan, Trodelvy
University of Kansas Medical Center, Novartis Pharmaceuticals, Gilead Sciences
Breast Cancer
12/24
12/25
Meric-Bernstam, Funda
TAPUR, NCT02693535: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer

Recruiting
2
3791
US
Palbociclib, Ibrance, Sunitinib, Sutent, Temsirolimus, Torisel, Trastuzumab and Pertuzumab, Herceptin and Perjeta, Vemurafenib and Cobimetinib, Zelboraf and Cotellic, Regorafenib, Stivarga, Olaparib, Lynparza, Pembrolizumab, Keytruda, Nivolumab and Ipilimumab, Opdivo and Yervoy, Abemaciclib, Verzenio, Talazoparib, Talzenna, Atezolizumab and PHESGO, Tecentriq and PHESGO, Atezolizumab and Talazoparib, Tecentriq and Talzenna, Entrectinib, Rozlytrek, Larotrectinib, Vitrakvi, Tucatinib plus Trastuzumab Subcutaneous (SC), Tukysa and Herceptin Hylecta, Futibatinib, Lytgobi
American Society of Clinical Oncology, AstraZeneca, Bayer, Bristol-Myers Squibb, Eli Lilly and Company, Genentech, Inc., Merck Sharp & Dohme LLC, Pfizer, Boehringer Ingelheim, Seagen Inc., Taiho Oncology, Inc.
Lymphoma, Non-Hodgkin, Multiple Myeloma, Advanced Solid Tumors
12/24
12/25
NCT04946864: A Study to Investigate the Safety, Tolerability, of APG-2575 as a Single Agent or in Combination for Breast Cancer

Recruiting
1/2
65
US
APG-2575, APG2575, Palbociclib
Ascentage Pharma Group Inc.
Breast Cancer, Solid Tumor, Adult
07/24
10/24
CBX-12-101, NCT04902872: Study of CBX-12 in Subjects With Advanced or Metastatic Refractory Solid Tumors

Active, not recruiting
1/2
130
US
CBX-12
Cybrexa Therapeutics
Solid Tumor, Adult, Epithelial Ovarian Cancer, Small Cell Lung Carcinoma, Breast Cancer, Colorectal Cancer, Pancreas Cancer, Appendix Cancer, Non-small Cell Lung Cancer, Gastric Cancer, Esophagus Cancer, Urothelial Carcinoma, Sarcoma
05/24
09/24
ZWI-ZW25-204, NCT05027139: A Study of Zanidatamab (ZW25) With Evorpacept (ALX148) in Patients With Advanced HER2-expressing Cancer

Active, not recruiting
1/2
52
US
Zanidatamab, ZW25, JZP598, Evorpacept, ALX148
Jazz Pharmaceuticals, ALX Oncology Inc.
HER2-expressing Cancers
10/24
04/25
StarBridge-1, NCT05320588: A Study in Patients With Advanced Cancers

Recruiting
1/2
332
US
BIO-106, Pembrolizumab, Keytruda
BiOneCure Therapeutics Inc.
Advanced Cancer, Advanced Solid Tumor, Cancer, Oncology
04/24
04/27
NCT04092673: Study of eFT226 in Subjects With Selected Advanced Solid Tumor Malignancies

Recruiting
1/2
30
US
eFT226, Selective translation inhibitor, Sotorasib, Lumarkus, Fulvestrant, Faslodex, Abemaciclib, Verzenia, Trastuzumab, Herceptin
Effector Therapeutics
Solid Tumor, Adult
12/24
03/25
NCT05548296: A Study of ACR-368 in Ovarian Carcinoma, Endometrial Adenocarcinoma, and Urothelial Carcinoma

Recruiting
1/2
390
US
ACR-368, prexasertib, Gemcitabine, OncoSignature
Acrivon Therapeutics, GOG Foundation
Platinum-resistant Ovarian Cancer, Endometrial Adenocarcinoma, Urothelial Carcinoma
07/26
12/27
NCT05941507: A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid Tumors

Recruiting
1/2
300
Canada, US
LCB84, Anti-PD-1 monoclonal antibody
LigaChem Biosciences, Inc., AntibodyChem Biosciences, Inc.
Advanced Solid Tumors
01/27
05/27
FONTANA, NCT05797168: Phase I/IIa Study for AZD5335 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Solid Tumors

Recruiting
1/2
150
Europe, Canada, Japan, US, RoW
AZD5335, AZD5305
AstraZeneca
Ovarian Cancer, Lung Adenocarcinoma
11/27
11/27
NCT04586270: A Study of TAS0612 in Participants With Advanced or Metastatic Solid Tumor Cancer

Recruiting
1
100
Europe, US
TAS0612
Taiho Oncology, Inc.
Advanced or Metastatic Solid Tumors
08/24
07/27
SGNCEA5C-001, NCT06131840: A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors

Recruiting
1
410
Canada, US
SGN-CEACAM5C, SAR445953
Seagen Inc., Sanofi
Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung, Stomach Neoplasms, Pancreatic Ductal Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Small Cell Lung Carcinoma
03/29
03/30
NCT06234423: A Study of CUSP06 in Patients With Platinum-Refractory/Resistant Ovarian Cancer and Other Advanced Solid Tumors

Recruiting
1
180
US
CUSP06
OnCusp Therapeutics, Inc.
Ovarian Cancer, Solid Tumor
05/27
08/27
NCT03843359: A First Time in Human (FTIH) Study of GSK3745417 Administered to Participants With Advanced Solid Tumors

Active, not recruiting
1
98
Europe, Canada, Japan, US, RoW
GSK3745417, Dostarlimab
GlaxoSmithKline
Neoplasms
03/25
03/25
NCT05527184: First in Human Study of IMGN151 in Recurrent Endometrial Cancer and Recurrent, High-grade Serous Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers

Recruiting
1
227
US
IMGN151
ImmunoGen, Inc.
Endometrial Cancer, High Grade Serous Adenocarcinoma of Ovary, Primary Peritoneal Carcinoma, Fallopian Tube Cancer
06/24
12/25
NCT04706962: TH1902 in Patients With Advanced Solid Tumors

Recruiting
1
70
Canada, US
TH1902, TH1902 peptide-drug conjugate
Theratechnologies, PPD, Altasciences Company Inc., Windtree Therapeutics, Syneos Health, Innovaderm Research Inc.
Solid Tumor, TNBC - Triple-Negative Breast Cancer, Hormone Receptor-positive Breast Cancer, Epithelial Ovarian Cancer, Endometrial Cancer, Cutaneous Melanoma, Thyroid Cancer, Small-cell Lung Cancer, Prostate Cancer, SORT1+ Cancers
12/24
12/24
NCT05753722: A First-in-human Study of PRTH-101 Monotherapy +/- Pembrolizumab in Subjects With Advanced Malignancies

Recruiting
1
270
US
PRTH-101, Pembrolizumab
Incendia Therapeutics
Advanced or Metastatic Solid Tumors
09/27
09/27
NCT04058756: Rollover Study for Continued Safety and Tolerability in Subjects Treated With Spartalizumab Alone or in Combination With Other Study Treatments

Recruiting
1
121
Europe, Canada, US, RoW
PDR001
Novartis Pharmaceuticals
Advanced Solid Tumors
04/30
04/30
NCT04507503: Expanded Access Study of TAS-120 in Patients With Advanced Cholangiocarcinoma Harboring FGFR2 Gene Rearrangements

Approved for marketing
N/A
US
TAS-120, Futibatinib
Taiho Oncology, Inc.
Advanced Cholangiocarcinoma
 
 
Westin, Shannon
DUO-E, NCT04269200 / 2019-004112-60: Durvalumab With or Without Olaparib as Maintenance Therapy After First-Line Treatment of Advanced and Recurrent Endometrial Cancer

Calendar Jan 2024 - Dec 2024: Acceptance of regulatory submission in combination with Imfinzi for endometrial cancer (based on DuO-E trial)
Calendar Jan 2024 - Dec 2024: Acceptance of regulatory submission in combination with Lynparza for endometrial cancer (based on DuO-E trial)
Hourglass Jan 2022 - Dec 2023 : Acceptance of regulatory submission in Japan in combination with Imfinzi (based on DuO-E trial) for 1L endometrial cancer
Hourglass Jan 2022 - Dec 2023 : Acceptance of regulatory submission in Japan in combination with Lynparza (based on DuO-E trial) for 1L endometrial cancer
Jul 2023 - Dec 2023: Data from DUO-E trial in combination with Imfinzi for 1L endometrial cancer
More
Active, not recruiting
3
805
Europe, Canada, Japan, US, RoW
olaparib, durvalumab, durvalumab placebo, olaparib placebo, Carboplatin, Paclitaxel
AstraZeneca, The Gynecologic Oncology Group (GOG) Foundation Inc, The European Network for Gynaecological Oncological Trial groups (ENGOT)
Endometrial Neoplasms
03/25
03/25
GOG-3026, NCT03673124: Ribociclib and Letrozole Treatment in Ovarian Cancer

Active, not recruiting
2
51
US
Ribociclib, Letrozole
Gynecologic Oncology Group, Novartis
Low Grade Serous Carcinoma
12/23
12/24
NCT05715216: EON: A Single-arm Phase II Study of Etigilimab (OMP-313M32) in Combination With Checkpoint Inhibition (Nivolumab) in Patients With Platinum-resistant, Recurrent Epithelial Ovarian Cancer

Recruiting
2
20
US
Nivolumab, BMS-936558, Opdivo, Etigilimab
M.D. Anderson Cancer Center, Mereo BioPharma
Ovarian Cancer
04/25
04/25
NCT05538624: A Study of Intraperitoneally Administered AVB-001 in Patients With Serous Adenocarcinoma of the Ovary

Terminated
1/2
14
US
AVB-001 (Dose Escalation Phase), AVB-001 (Dose Expansion Phase)
Avenge Bio, Inc
Neoplasm, Ovarian, Fallopian Tube Cancer, Primary Peritoneal Cavity Cancer, Adenocarcinoma Ovary, Serous Adenocarcinoma of Ovary, Serous Adenocarcinoma of Primary Peritoneum, Primary Peritoneal Carcinoma, High Grade Serous Adenocarcinoma
04/24
04/24
NCT04196257: BP1001-A in Patients With Advanced or Recurrent Solid Tumors

Recruiting
1
50
US
BP1001-A (Liposomal Grb2 Antisense Oligonucleotide), BP1001-A (Liposomal Grb2 Antisense Oligonucleotide) with paclitaxel
Bio-Path Holdings, Inc.
Solid Tumor, Adult, Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Endometrial Cancer, Peritoneal Cancer, Solid Tumor
07/24
10/24
NCT05636111: Phase 1b of Lurbinectedin in Combination With Weekly Paclitaxel and Bevacizumab in Platinum-resistant Ovarian Cancer

Recruiting
1
34
US
Paclitaxel, Taxol, Bevacizumab, Avastin™, Anti-VEGF monoclonal antibody, rhuMAb-VEGF, Lurbinectedin
M.D. Anderson Cancer Center, Jazz Pharmaceuticals
Ovarian Cancer
07/24
07/26
NCT03162627: Selumetinib and Olaparib in Solid Tumors

Active, not recruiting
1
90
US
Selumetinib, AZD6244, Olaparib, Lynparza
M.D. Anderson Cancer Center, AstraZeneca
Malignant Neoplasm of Breast, Malignant Neoplasms of Digestive Organs, Malignant Neoplasms of Female Genital Organs, Malignant Neoplasms of Male Genital Organs, Malignant Neoplasms of Thyroid and Other Endocrine Glands
08/26
08/26
Corn, Paul
NCT01254864: Maximal Androgen Depletion Followed by Randomization of Maximal Androgen Ablation With Molecular Targeted Therapies

Completed
2
190
US
Abiraterone Acetate, CB7630, Prednisone, Sunitinib, Sunitinib Malate, SUO11248, Sutent, Dasatinib, BMS-354825, Sprycel
M.D. Anderson Cancer Center, Bristol-Myers Squibb, Janssen Scientific Affairs, LLC, Pfizer
Prostate Cancer
12/23
12/23
Heymach, John
AEGEAN, NCT03800134 / 2018-002997-29: A Study of Neoadjuvant/Adjuvant Durvalumab for the Treatment of Patients With Resectable Non-small Cell Lung Cancer

Calendar Jan 2024 - Dec 2024: Event free survival data from AEGEAN trial for stage I and III resected NSCLC
Jan 2023 - Dec 2023: Regulatory submission for locally advanced stage 3 NSCLC (based on AEGEAN trial)
Hourglass Jan 2022 - Dec 2023 : Regulatory submission in EU for advanced stage 3 NSCLC (based on AEGEAN trial)
Hourglass Jan 2022 - Dec 2023 : Regulatory submission in Japan for advanced stage 3 NSCLC (based on AEGEAN trial)
Jan 2023 - Dec 2023: From AEGEAN trial for stage II and III resected NSCLC
More
Active, not recruiting
3
826
Europe, Canada, Japan, US, RoW
Durvalumab, MEDI4736, Placebo, Carboplatin, Cisplatin, Pemetrexed, Paclitaxel, Gemcitabine, Surgery
AstraZeneca
Non-Small Cell Lung Cancer
11/22
09/28
HUDSON, NCT03334617 / 2017-002208-28: Phase II Umbrella Study of Novel Anti-cancer Agents in Patients With NSCLC Who Progressed on an Anti-PD-1/PD-L1 Containing Therapy

Calendar Jan 2024 - Dec 2024: Data from HUDSON trial for NSCLC
Active, not recruiting
2
531
Europe, Canada, US, RoW
Durvalumab, AZD9150, AZD6738, Vistusertib, Olaparib, Oleclumab, trastuzumab deruxtecan, cediranib, AZD6738 (ceralasertib), AZD6738 (ceralasertib) (240 mg or 160 mg), AZD6738 (ceralasertib) 7 days monotherapy
AstraZeneca
Non-Small Cell Lung Cancer
09/24
09/24
Jabbour, Salma
NCT05366829: Tislelizumab Consolidation After Liver-Directed Therapy for Hepatocellular Carcinoma

Recruiting
2
35
US
Tislelizumab
Rutgers, The State University of New Jersey, BioGene Pharmaceutical Ltd., Natera, Inc.
Carcinoma, Hepatocellular, Liver Cell Carcinoma
06/27
06/27
BTCRC-LUN17-127, NCT03575793: A Phase I/II Study of Nivolumab, Ipilimumab and Plinabulin in Patients With Recurrent Small Cell Lung Cancer

Checkmark Initial data from trial in combination with opdivo and yervoy for recurrent small cell lung cancer at ASCO 2021
Jun 2021 - Jun 2021: Initial data from trial in combination with opdivo and yervoy for recurrent small cell lung cancer at ASCO 2021
Checkmark Data from combination with nivolumab and ipilimumab for 2L & 3L SCLC
May 2021 - May 2021: Data from combination with nivolumab and ipilimumab for 2L & 3L SCLC
Checkmark From trial in combination with nivolumab and plinabulin for recurrent SCLC at ASCO 2021
More
Active, not recruiting
1/2
39
US
Nivolumab, Opdivo, Plinabulin, Ipilimumab, Yervoy
Salma Sabbour, BeyondSpring Pharmaceuticals Inc., Bristol-Myers Squibb, Rutgers Cancer Institute of New Jersey
Lung Cancer, SCLC
09/23
07/24
NCT02621398: Pembrolizumab, Paclitaxel, Carboplatin, and Radiation Therapy in Treating Patients With Stage II-IIIB Non-Small Cell Lung Cancer

Active, not recruiting
1
23
US
3-Dimensional Conformal Radiation Therapy, 3-dimensional radiation therapy, 3D-CRT, Conformal Therapy, Radiation Conformal Therapy, Carboplatin, Blastocarb, Carboplat, Carboplatin Hexal, Carboplatino, Carbosin, Carbosol, Carbotec, CBDCA, Displata, Ercar, JM-8, Nealorin, Novoplatinum, Paraplat, Paraplatin, Paraplatin AQ, Paraplatine, Platinwas, Ribocarbo, Intensity-Modulated Radiation Therapy, IMRT, Intensity Modulated RT, Intensity-Modulated Radiotherapy, Laboratory Biomarker Analysis, Paclitaxel, Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, Pembrolizumab, Keytruda, Lambrolizumab, MK-3475, SCH 900475
Rutgers, The State University of New Jersey, National Cancer Institute (NCI), Rutgers Cancer Institute of New Jersey, Merck Sharp & Dohme LLC
Stage II Non-Small Cell Lung Cancer, Stage IIIA Non-Small Cell Lung Cancer, Stage IIIB Non-Small Cell Lung Cancer
10/19
12/42
 

Download Options